세계의 삼차 신경통 치료 시장 보고서(2025년)
Trigeminal Neuralgia Treatment Global Market Report 2025
상품코드 : 1720914
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ₩ 6,675,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ₩ 9,648,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ₩ 12,622,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

삼차 신경통 치료 시장 규모는 앞으로 수년간 강력한 성장이 예상됩니다. 2029년에는 CAGR 6.7%로 9억 5,000만 달러로 성장할 것으로 예상됩니다. 예측기간의 성장은 헬스케어 전문가나 일반주민의 삼차 신경통에 대한 인지도의 향상, TN사례 증가, 노인 증가, 의료비 증가, 진단사례 수 증가 등에 기인하는 것으로 예측됩니다. 주요 동향으로는 신경조절 기술의 진보, 조사 기술의 향상, 의료 연구와 기술의 진보, 저침습 수술 기술의 채택, 디지털 헬스 기술의 통합 등을 들 수 있습니다.

신경질환의 유병률 증가는 앞으로 수 년간 삼차 신경통 치료 시장의 확대를 촉진할 것으로 예측됩니다. 신경 질환에는 뇌, 척수, 신경을 포함한 신경계에 영향을 미치는 질환이 포함됩니다. 유전적 소인, 감염, 외상, 독소, 자가면역 반응, 변성 등 다양한 요인들이 이러한 질병의 유병률 상승에 기여하고 있습니다. 삼차 신경통 치료는 심한 안면 통증 완화, 신경 자극 완화, QOL 향상, 통증 관리, 추가 신경 장애 예방을 통해 신경 질환 환자를 지원합니다. 예를 들어, 2022년 4월 벨기에에 기반을 둔 비영리 단체인 European Brain Council의 데이터에 따르면, 600개 이상의 신경질환과 300개의 정신질환이 전 세계 수백만 명에게 영향을 미치고 있으며 6,500만 명의 간질환자가 포함되어 있습니다. 유럽만으로도 1,050만명이 치매이며, 2050년에는 1,870만명으로 증가할 것으로 예측되고 있습니다. 그 결과, 신경질환의 이환율 증가가 삼차 신경통 치료에 대한 수요를 촉진할 것으로 예측됩니다.

삼차 신경통 치료 시장의 주요기업은 규제당국의 승인을 받아 시장에서의 존재를 확대하기 위해 시험용 신약(IND) 신청에 주력하고 있습니다. IND 신청을 통해 제약 회사는 규제 당국에 승인을 요청하여 인체 임상 검사를 시작하고 의약품의 안전성, 효능 및 적절한 복용량을 평가할 수 있습니다. 예를 들어, 스위스에 기반을 둔 임상 단계의 생명 공학 기업인 Noema Pharma는 2022년 2월, 삼차 신경통(TN)을 대상으로 mGluR5 억제제 NOE-101의 2b상 임상 검사를 시작하기 위한 IND 승인을 미국 식품의약국(FDA)으로부터 취득했습니다. LibraTN 연구는 성인의 삼차 신경통(TN) 관련 통증에 대한 NOE-101의 효능과 안전성을 평가하는 24주간의 다기관, 위약 대조 임상시험이며, 2024년 상반기에 결과가 나올 예정입니다. 또한 FDA는 바심 글루란트(NOE-101)의 개발과 약사 심사 프로세스를 가속화하기 위해 패스트 트랙 지정을 실시했습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 거시경제 시나리오 금리, 인플레이션, 지정학, 신형 코로나 바이러스 감염의 영향과 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 전략

제36장 부록

SHW
영문 목차

영문목차

Trigeminal neuralgia treatment involves medical strategies to manage the severe, sharp facial pain caused by trigeminal neuralgia, which affects the trigeminal nerve. The primary goal of treatment is to alleviate pain, reduce the frequency and intensity of episodes, and address underlying nerve irritation, ultimately improving the patient's quality of life.

The main types of trigeminal neuralgia treatment include medications, surgery, and other therapeutic approaches. Medications are formulated to reduce pain by controlling nerve activity. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are utilized by several end-users, such as hospitals, specialty clinics, and ambulatory surgical centers.

The trigeminal neuralgia treatment market research report is one of a series of new reports from The Business Research Company that provides trigeminal neuralgia treatment market statistics, including the trigeminal neuralgia treatment industry global market size, regional shares, competitors with the trigeminal neuralgia treatment market share, detailed trigeminal neuralgia treatment market segments, market trends, and opportunities, and any further data you may need to thrive in the trigeminal neuralgia treatment industry. This trigeminal neuralgia treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The trigeminal neuralgia treatment market size has grown strongly in recent years. It will grow from $0.68 billion in 2024 to $0.73 billion in 2025 at a compound annual growth rate (CAGR) of 7.1%. The growth during the historic period can be attributed to the increasing incidence of chronic diseases, the rising prevalence of neurological disorders and trigeminal neuralgia, the growing demand for minimally invasive treatments, and the increasing preference for minimally invasive surgeries.

The trigeminal neuralgia treatment market size is expected to see strong growth in the next few years. It will grow to $0.95 billion in 2029 at a compound annual growth rate (CAGR) of 6.7%. The growth in the forecast period can be attributed to increasing awareness of trigeminal neuralgia among healthcare professionals and the general population, a rise in TN cases, a growing geriatric population, increasing healthcare expenditure, and a higher number of diagnosed cases. Major trends include advancements in neuromodulation techniques, improvements in TENS technology, progress in medical research and technology, the adoption of minimally invasive surgical techniques, and the integration of digital health technologies.

The increasing prevalence of neurological disorders is expected to drive the expansion of the trigeminal neuralgia treatment market in the coming years. Neurological disorders encompass conditions that affect the nervous system, including the brain, spinal cord, and nerves. Various factors contribute to the rising prevalence of these disorders, such as genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Trigeminal neuralgia treatment helps neurological patients by alleviating severe facial pain, reducing nerve irritation, improving quality of life, managing pain, and preventing further neurological damage. For example, in April 2022, data from the European Brain Council, a Belgium-based non-profit organization, indicated that more than 600 neurological diseases and nearly 300 psychiatric conditions impact millions worldwide, including 65 million people with epilepsy. In Europe alone, 10.5 million individuals have dementia, with projections estimating an increase to 18.7 million by 2050. Consequently, the growing incidence of neurological disorders is expected to fuel the demand for trigeminal neuralgia treatments.

Leading companies in the trigeminal neuralgia treatment market are focusing on investigational new drug (IND) applications to obtain regulatory approvals and expand their market presence. An IND application allows pharmaceutical companies to seek approval from regulatory agencies to begin human clinical trials, assessing a drug's safety, efficacy, and appropriate dosage. For instance, in February 2022, Noema Pharma, a Switzerland-based clinical-stage biotechnology company, received IND approval from the U.S. Food and Drug Administration (FDA) to initiate a Phase 2b clinical trial for the mGluR5 inhibitor NOE-101 in trigeminal neuralgia (TN). The LibraTN study is a 24-week, multi-center, placebo-controlled trial evaluating the efficacy and safety of NOE-101 in adults experiencing TN-related pain, with results expected in the first half of 2024. Additionally, the FDA granted fast track designation to basimglurant (NOE-101) to accelerate its development and regulatory review process.

In October 2022, Pfizer Inc., a U.S.-based pharmaceutical company, acquired Biohaven Pharmaceuticals for approximately $11.6 billion. This acquisition aims to strengthen Pfizer's neurology portfolio by securing full rights to Biohaven Pharmaceuticals' migraine treatments, including Nurtec ODT (rimegepant) and other CGRP receptor antagonists. The deal enhances Pfizer's leadership in the migraine treatment market while expanding its pipeline of innovative neurological therapies. Biohaven Pharmaceuticals, a U.S.-based pharmaceutical company, has also been involved in researching and developing potential treatments for trigeminal neuralgia, including rimegepant.

Major players in the trigeminal neuralgia treatment market are Aetna Inc., Thermo Fisher Scientific Inc., Novartis AG, Sandoz, Sun Pharmaceutical Industries Ltd., Apotex Inc., Lupin Limited, Taro Pharmaceutical Industries Ltd., Torrent Pharmaceuticals Ltd., Kriya Therapeutics, Convergence Pharmaceuticals Limited, Noema Pharma AG, Max Healthcare, Initiator Pharma AS, Coda Biotherapeutics Inc., Oxford Cannabinoid Technologies Holdings Plc, NanoVibronix, Biogen Idec, Shanghai SIMR Biotechnology Co. Ltd., Capnia Inc.

North America was the largest region in the trigeminal neuralgia treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the trigeminal neuralgia treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The trigeminal neuralgia treatment market consists of revenues earned by entities by providing services such as physical therapy, patient education, and supportive care. The market value includes the value of related goods sold by the service provider or included within the service offering. The trigeminal neuralgia treatment market also includes sales of anticonvulsants, muscle relaxants, and tricyclic antidepressants (TCAs). Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Trigeminal Neuralgia Treatment Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on trigeminal neuralgia treatment market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for trigeminal neuralgia treatment ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The trigeminal neuralgia treatment market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Trigeminal Neuralgia Treatment Market Characteristics

3. Trigeminal Neuralgia Treatment Market Trends And Strategies

4. Trigeminal Neuralgia Treatment Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Trigeminal Neuralgia Treatment Growth Analysis And Strategic Analysis Framework

6. Trigeminal Neuralgia Treatment Market Segmentation

7. Trigeminal Neuralgia Treatment Market Regional And Country Analysis

8. Asia-Pacific Trigeminal Neuralgia Treatment Market

9. China Trigeminal Neuralgia Treatment Market

10. India Trigeminal Neuralgia Treatment Market

11. Japan Trigeminal Neuralgia Treatment Market

12. Australia Trigeminal Neuralgia Treatment Market

13. Indonesia Trigeminal Neuralgia Treatment Market

14. South Korea Trigeminal Neuralgia Treatment Market

15. Western Europe Trigeminal Neuralgia Treatment Market

16. UK Trigeminal Neuralgia Treatment Market

17. Germany Trigeminal Neuralgia Treatment Market

18. France Trigeminal Neuralgia Treatment Market

19. Italy Trigeminal Neuralgia Treatment Market

20. Spain Trigeminal Neuralgia Treatment Market

21. Eastern Europe Trigeminal Neuralgia Treatment Market

22. Russia Trigeminal Neuralgia Treatment Market

23. North America Trigeminal Neuralgia Treatment Market

24. USA Trigeminal Neuralgia Treatment Market

25. Canada Trigeminal Neuralgia Treatment Market

26. South America Trigeminal Neuralgia Treatment Market

27. Brazil Trigeminal Neuralgia Treatment Market

28. Middle East Trigeminal Neuralgia Treatment Market

29. Africa Trigeminal Neuralgia Treatment Market

30. Trigeminal Neuralgia Treatment Market Competitive Landscape And Company Profiles

31. Trigeminal Neuralgia Treatment Market Other Major And Innovative Companies

32. Global Trigeminal Neuralgia Treatment Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Trigeminal Neuralgia Treatment Market

34. Recent Developments In The Trigeminal Neuralgia Treatment Market

35. Trigeminal Neuralgia Treatment Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기